Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Human Clinical Study on TurboCBD Capsules Corroborates Earlier DehydraTECH Test Results
Significant bioavailability results were reported from LXRP’s randomized, double-blind European study that evaluated its proprietary TurboCBD capsules, powered by DehydraTECH Results corroborate and confirm in vitro and in vivo studies of DehydraTECH technology that measured high levels of drug delivery being achieved faster than with matching controls LXRP says that it is pleased that DehydraTECH has, to date, repeatedly proved evidence of success within human studies; technology earlier demonstrated ability to deliver nicotine Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is pleased to report significant bioavailability results from its randomized and double-blind European human clinical study of DehydraTECH™ powered TurboCBD™…